David GIN,Michelle ADAMS,Kai DENG,Philip LIVINGSTON,Govindaswami RAGUPATHI,Eric CHEA,Alberto FERNANDEZ-TEJADA,Lars Ulrik NORDSTROEM,William WALKOWICZ,Jeffrey GARDNER,Derek TAN
申请号：
US15626046
公开号：
US20170283450A1
申请日:
2017.06.16
申请国别(地区):
US
年份:
2017
代理人:
摘要：
The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation.
